587 related articles for article (PubMed ID: 32542562)
1. The Treatment of Pediatric Inflammatory Bowel Disease with Biologic Therapies.
Conrad MA; Kelsen JR
Curr Gastroenterol Rep; 2020 Jun; 22(8):36. PubMed ID: 32542562
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
3. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
5. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Bossa F; Carparelli S; Latiano A; Palmieri O; Tavano F; Panza A; Pastore M; Marseglia A; D'Altilia M; Latiano T; Corritore G; Martino G; Nardella M; Guerra M; Terracciano F; Sacco M; Perri F; Andriulli A
Dig Liver Dis; 2021 Mar; 53(3):277-282. PubMed ID: 33423942
[TBL] [Abstract][Full Text] [Related]
6. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
[TBL] [Abstract][Full Text] [Related]
7. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
[TBL] [Abstract][Full Text] [Related]
8. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
[TBL] [Abstract][Full Text] [Related]
9. Managing Risks with Biologics.
Click B; Regueiro M
Curr Gastroenterol Rep; 2019 Jan; 21(2):1. PubMed ID: 30635807
[TBL] [Abstract][Full Text] [Related]
10. Biological treatment approach to inflammatory bowel disease is similar in academic and nonacademic centres - prime time for decentralisation of inflammatory bowel disease care?
Tepeš K; Hanžel J; Štubljar D; Strmšek K; Erjavec L; Supovec E; Jagodic Z; Končan M; Grosek J; Košir JA; Tomažič A; Kogovšek U; Norčič G; Šibli R; Žnidaršič M; Pačnik Vižintin T; Sodin B; Breznik J; Hribar VA; Ocepek A; Pernat Drobež C; Bukovnik N; Zafošnik A; Marušič T; Jurečič Brglez N; Denkovski M; Smrekar N; Novak G; Koželj M; Kurent T; Simonič J; Pintar Š; Štabuc B; Drobne D
Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):728-734. PubMed ID: 38625825
[TBL] [Abstract][Full Text] [Related]
11. Special considerations for biologic medications in pediatric ulcerative colitis.
Jerger L; Hyams JS
Expert Opin Biol Ther; 2020 Apr; 20(4):429-435. PubMed ID: 31652087
[No Abstract] [Full Text] [Related]
12. Biologic Therapy for Ulcerative Colitis.
Bhattacharya A; Osterman MT
Gastroenterol Clin North Am; 2020 Dec; 49(4):717-729. PubMed ID: 33121691
[TBL] [Abstract][Full Text] [Related]
13. Two Strikes but Not Out: Deep Remission of Ulcerative Colitis with Ustekinumab After Primary Non-response to Infliximab and Vedolizumab.
Dalal RS; Ananthakrishnan AN; Hamilton MJ; Winter RW
Dig Dis Sci; 2021 Mar; 66(3):733-737. PubMed ID: 33569666
[No Abstract] [Full Text] [Related]
14. Difficult-to-treat inflammatory bowel disease: Effectiveness and safety of 4th and 5th lines of treatment.
Caron B; Habert A; Bonsack O; Camara H; Jeanbert E; Parigi TL; Netter P; Danese S; Peyrin-Biroulet L
United European Gastroenterol J; 2024 Jun; 12(5):605-613. PubMed ID: 38594841
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease.
Dutt K; Vasudevan A
Medicina (Kaunas); 2024 Jan; 60(2):. PubMed ID: 38399538
[No Abstract] [Full Text] [Related]
16. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease.
Restellini S; Khanna R; Afif W
Inflamm Bowel Dis; 2018 Sep; 24(10):2165-2172. PubMed ID: 29788272
[TBL] [Abstract][Full Text] [Related]
18. Precision Dosing of Anti-TNF Therapy in Pediatric Inflammatory Bowel Disease.
Samuels A; Whaley KG; Minar P
Curr Gastroenterol Rep; 2023 Nov; 25(11):323-332. PubMed ID: 37695555
[TBL] [Abstract][Full Text] [Related]
19. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
Ribaldone DG; Pellicano R; Vernero M; Caviglia GP; Saracco GM; Morino M; Astegiano M
Scand J Gastroenterol; 2019 Apr; 54(4):407-413. PubMed ID: 30945576
[No Abstract] [Full Text] [Related]
20. The role of biologics in the treatment of patients with inflammatory bowel disease.
Selinger CP; Carbery I; Al-Asiry J
Br J Hosp Med (Lond); 2018 Dec; 79(12):686-693. PubMed ID: 30526103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]